Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: A nationwide, long-term survey

Journal of Gastroenterology

Volumn 47, Issue 12, 2012, Pages 1308-1322

  Baars, J E ^a   Kuipers, E J ^a   Van Haastert, M ^b   Nicolai J J ^c   Poen, A C ^d   Van Der Woude, C J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

^c HAGA HOSPITAL   (Netherlands)

^d ISALA HOSPITAL   (Netherlands)

Author keywords

Colorectal carcinoma; Crohn's disease; Risk factor; Ulcerative colitis

Indexed keywords

ADULT; AGE; AGE AT DIAGNOSIS; AGE DISTRIBUTION; AGED; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; COHORT ANALYSIS; COLITIS; COLORECTAL CANCER; CROHN DISEASE; DISEASE SEVERITY; DISEASE SURVEILLANCE; ENTERITIS; FEMALE; GENERAL HOSPITAL; HEALTH SURVEY; HOSPITAL INFORMATION SYSTEM; HUMAN; INTESTINE POLYP; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; ONSET AGE; POPULATION RESEARCH; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; ULCERATIVE COLITIS;

ADULT; AGE FACTORS; AGE OF ONSET; AGED; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; POPULATION SURVEILLANCE; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84875759712     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0603-2     Document Type: Review

References (44)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-35. (Pubitemid 32234798)
2. Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(Suppl 4):24-30. (Pubitemid 39319243)
3. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724-9.
4. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995;22:1404-8.
5. Velayos FS, Loftus EV Jr, Jess T, Harmsen WS, Bida J, Zinsmeister AR, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130:1941-9. (Pubitemid 43816957)
6. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813-6. (Pubitemid 39556902)
7. Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120:1356-62. (Pubitemid 32322309)
8. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-9. (Pubitemid 38182302)
9. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228-33. (Pubitemid 20366527)
10. Gyde SN, Prior P, Allan RN, Stevens A, Jewell DP, Truelove SC, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut. 1988;29:206-17. (Pubitemid 18078890)
11. Sugita A, Sachar DB, Bodian C, Ribeiro MB, Aufses AH, Jr., Greenstein AJ. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut. 1991;32:167-9.
12. Kvist N, Jacobsen O, Kvist HK, Norgaard P, Ockelmann HH, Schou G, et al. Malignancy in ulcerative colitis. Scand J Gastroenterol. 1989;24:497-506. (Pubitemid 19141437)
13. Brackmann S, Andersen SN, Aamodt G, Langmark F, Clausen OP, Aadland E, et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol. 2009;44:46-55.
14. Lutgens MW, Vleggaar FP, Schipper ME, Stokkers PC, van der Woude CJ, Hommes DW, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut. 2008;57:1246-51.
15. Choi PM, Nugent FW, Schoetz DJ Jr, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology. 1993;105:418-24. (Pubitemid 23213526)
16. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2006;CD000279.
17. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51(Suppl 5):V10-2.
18. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124:544-60. (Pubitemid 36169269)
19. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(746-74):774.
20. Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A et al. European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohn's Colitis. 2008;2:63-92.
21. Casparie MK, Tiebosch ATMG, Burger G, Blauwgeers H, Pol van de A., van Krieken JHJM et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29:19-24. (Pubitemid 46535194)
22. Steyerberg EW, Eijkemans MJ, Harrell FE Jr, Habbema JD. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med. 2000;19:1059-79. (Pubitemid 30238915)
23. Risques RA, Lai LA, Brentnall TA, Li L, Feng Z, Gallaher J, et al. Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology. 2008;135:410-8.
24. Brackmann S, Andersen SN, Aamodt G, Roald B, Langmark F, Clausen OP, et al. Two distinct groups of colorectal cancer in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:9-16.
25. van Rijn AF, Fockens P, Siersema PD, Oldenburg B. Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn's colitis patients in the Netherlands. World J Gastroenterol. 2009;15:226-30.
26. CBO guideline for diagnosis and treatment of inflammatory bowel diseases in adult patients 2009. 2011.
27. Rozen P, Baratz M, Fefer F, Gilat T. Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology. 1995;108:1361-70.
28. Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1996;110:331-8. (Pubitemid 26043863)
29. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997;41:522-5.
30. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1999;94:1643-9. (Pubitemid 29260459)
31. Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study. Cancer. 1998;82:822-6. (Pubitemid 28104159)
32. Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum. 2001;44:77-85. (Pubitemid 32105878)
33. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-8. (Pubitemid 41531774)
34. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-53. (Pubitemid 40904360)
35. Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:675-712. (Pubitemid 44314185)
36. Soderlund S, Granath F, Brostrom O, Karlen P, Lofberg R, Ekbom A, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010;138:1697-703.
37. Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124:880-8. (Pubitemid 36389789)
38. Kleer CG, Appelman HD. Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. Am J Surg Pathol. 1998;22:983-9. (Pubitemid 28364498)
39. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991;32:174-8.
40. Geboes K, Ectors N, D'Haens G, Rutgeerts P. Is ileoscopy with biopsy worthwhile in patients presenting with symptoms of inflammatory bowel disease? Am J Gastroenterol. 1998;93:201-6. (Pubitemid 29063967)
41. Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, et al. European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis. 2008;2:63-92. (Pubitemid 351179489)
42. Van Schaik et al. Substantial increase of progression rate of flat low-grade dysplasia in inflammatory bowel disease after review by an expert panel. Dutch Society of Gastroenterology & Hepatology (NVGE), Veldhoven, The Netherlands. 2010.
43. http://www.cijfersoverkanker.nl. 2012
44. Baars JE, Looman CW, Steyerberg EW, Beukers R, Tan AC, Weusten BL et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol. 2010;106(2):319-328.